Tailored Liposomal Nanomedicine Suppresses Incomplete Radiofrequency Ablation‐Induced Tumor Relapse by Reprogramming Antitumor Immunity
Advanced Healthcare Materials · 2025-04 · 14 (9)
DOI: 10.1002/adhm.202403979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 17.02.2025. Verfasst von Duo Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 2240…. Hauptthemen laut MEDLINE: Liposomes, Radiofrequency Ablation, Nanomedicine, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Postdoctoral Fellowship Program of CPSF, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Radiofrequency ablation (RFA), a thermoablative treatment for small hepatocellular carcinoma (HCC), has limited therapeutic benefit for advanced HCC patients with large, multiple, and/or irregular tumors owing to incomplete RFA (iRFA) of the tumor mass. It is first identified that iRFA‐treated tumors exhibited increased pyruvate kinase M2 (PKM2) expression, exacerbated tumor immunosuppression featured with increased tumor infiltration of suppressive immune cells and increased proliferation, and programmed cell death ligand 1 expression of cancer cell and ultimately a poor prognosis. Herein, a multifunctional nanomedicine is fabricated by encapsulating nanoassemblies of anti‐PD‐L1 and spermidine‐grafted oxidized dextran with shikonin‐containing lipid bilayers to reverse iRFA‐induced treatment failure. Shikonin, a PKM2 inhibitor, is used to suppress glycolysis in cancer cells, while anti‐PD‐L1 and spermidine are introduced to collectively reprogram the proliferation and functions of infiltrated CD8+ T lymphocytes. Combined with iRFA, which promoted the exposure of tumor antigens, the intravenous injection of liposomal SPS‐NPs effectively stimulated dendritic cell maturation and reversed tumor immunosuppression, thus eliciting potent antitumor immunity to synergistically suppress the growth of residual tumor masses and lung metastasis. The as‐prepared liposomal nanomedicine is promising for potentiating the therapeutic benefits of RFA toward advanced HCC patients through reprogramming iRFA‐induced tumor immunosuppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, 224001, China.
- Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, 224001, China.
- Department of Otorhinolaryngology Head and Neck Surgery, Guangzhou Twelfth People's Hospital (The Affiliated Twelfth People's Hospital of Guangzhou Medical University), Guangzhou Medical University, Guangzhou, 510620, C…
- Medical Research Center, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518033, China.
- Department of Medical Ultrasound, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.
- Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, 215123, China.
ORCID-Profile: Liangzhu Feng
Förderung
- Postdoctoral Fellowship Program of CPSF
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Science and Technology Program of Guangzhou
- Guangdong Basic and Applied Basic Research Foundation
- Natural Science Foundation of Jiangsu Province
- Research Personnel Cultivation Program of Zhongda Hospital Southeast University
Zitieren
APA
Wang, D., Nie, T., Fang, Y., Zhang, L., Yu, C., Yang, M., Du, R., Liu, J., Zhang, L., Feng, L., & Zhu, H. (2025). Tailored Liposomal Nanomedicine Suppresses Incomplete Radiofrequency Ablation‐Induced Tumor Relapse by Reprogramming Antitumor Immunity. Advanced Healthcare Materials, 14(9). https://doi.org/10.1002/adhm.202403979
Vancouver
Wang D, Nie T, Fang Y, Zhang L, Yu C, Yang M, et al. Tailored Liposomal Nanomedicine Suppresses Incomplete Radiofrequency Ablation‐Induced Tumor Relapse by Reprogramming Antitumor Immunity. Advanced Healthcare Materials. 2025;14(9). doi:10.1002/adhm.202403979
BibTeX
@article{Wang2025,
author = {Wang, Duo and Nie, Tianqi and Fang, Yifei and Zhang, Linzhu and Yu, Chao and Yang, Ming and Du, Ruijie and Liu, Junjie and Zhang, Lei and Feng, Liangzhu and Zhu, Haidong},
title = {Tailored Liposomal Nanomedicine Suppresses Incomplete Radiofrequency Ablation‐Induced Tumor Relapse by Reprogramming Antitumor Immunity},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {9},
doi = {10.1002/adhm.202403979}
}
EUVIMED